aid: 858-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/858-therapeutics.png
name: 858 Therapeutics
description: >-
  858 Therapeutics is a clinical-stage biotechnology company based in San Diego, California,
  developing first-in-class and best-in-class small-molecule therapies that target tumor
  dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral,
  potent, and selective PARG (poly(ADP-ribose) glycohydrolase) inhibitor being evaluated in a
  Phase 1/2 study for patients with advanced solid tumors, exploiting cancer-cell vulnerabilities
  tied to replication stress and defects in replication-fork protection. The company was surfaced
  as a portfolio company of Insight Partners and added to the API Evangelist network. As a
  clinical-stage therapeutics company it publishes a corporate and scientific web presence but
  no public developer, API, or documentation surface, so API artifacts are not applicable.
url: https://raw.githubusercontent.com/api-evangelist/858-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biotech
- Therapeutics
- Oncology
- Precision Medicine
- Drug Discovery
- DNA Damage Response
- Clinical Stage
- Pharmaceuticals
apis: []
common:
- type: Website
  url: https://8five8tx.com/
- type: Blog
  url: https://8five8tx.com/news/
- type: Support
  url: https://8five8tx.com/contact/
- type: DomainSecurity
  url: security/858-therapeutics-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence